Skip header and navigation

1 records – page 1 of 1.

APOE and AßPP gene variation in cortical and cerebrovascular amyloid-ß pathology and Alzheimer's disease: a population-based analysis.

https://arctichealth.org/en/permalink/ahliterature133862
Source
J Alzheimers Dis. 2011;26(2):377-85
Publication Type
Article
Date
2011
Author
Terhi Peuralinna
Maarit Tanskanen
Mira Mäkelä
Tuomo Polvikoski
Anders Paetau
Hannu Kalimo
Raimo Sulkava
John Hardy
Shiao-Lin Lai
Sampath Arepalli
Dena Hernandez
Bryan J Traynor
Andrew Singleton
Pentti J Tienari
Liisa Myllykangas
Author Affiliation
University of Helsinki, Research Program of Molecular Neurology, Biomedicum-Helsinki, Helsinki, Finland.
Source
J Alzheimers Dis. 2011;26(2):377-85
Date
2011
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alleles
Alzheimer Disease - genetics - metabolism - pathology
Amyloid beta-Peptides - genetics - metabolism
Amyloid beta-Protein Precursor - genetics - metabolism
Apolipoproteins E - genetics - metabolism
Cerebral Amyloid Angiopathy - genetics - metabolism - pathology
Cerebral Cortex - metabolism - pathology
Female
Finland
Genetic Association Studies
Genetic Variation
Humans
Male
Middle Aged
Phenotype
Promoter Regions, Genetic
Abstract
Cortical and cerebrovascular amyloid-? (A?) deposition is a hallmark of Alzheimer's disease (AD), but also occurs in elderly people not affected by dementia. The apolipoprotein E (APOE) e4 is a major genetic modulator of A? deposition and AD risk. Variants of the amyloid-? protein precursor (A?PP) gene have been reported to contribute to AD and cerebral amyloid angiopathy (CAA). We analyzed the role of APOE and A?PP variants in cortical and cerebrovascular A? deposition, and neuropathologically verified AD (based on modified NIA-RI criteria) in a population-based autopsy sample of Finns aged = 85 years (Vantaa85 + Study; n = 282). Our updated analysis of APOE showed strong associations of the e4 allele with cortical (p = 4.91 ? 10-17) and cerebrovascular (p = 9.87 ? 10-11) A? deposition as well as with NIA-RI AD (p = 1.62 ? 10-8). We also analyzed 60 single nucleotide polymorphisms (SNPs) at the A?PP locus. In single SNP or haplotype analyses there were no statistically significant A?PP locus associations with cortical or cerebrovascular A? deposition or with NIA-RI AD. We sequenced the promoter of the A?PP gene in 40 subjects with very high A? deposition, but none of these subjects had any of the previously reported or novel AD-associated mutations. These results suggest that cortical and cerebrovascular A? depositions are useful quantitative traits for genetic studies, as highlighted by the strong associations with the APOE e4 variant. Promoter mutations or common allelic variation in the A?PP gene do not have a major contribution to cortical or cerebrovascular A? deposition, or very late-onset AD in this Finnish population based study.
Notes
Cites: Nat Genet. 2009 Oct;41(10):1088-9319734902
Cites: CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-3019275634
Cites: Curr Pharm Des. 2010;16(25):2766-7820698820
Cites: Neuropathol Appl Neurobiol. 2011 Apr;37(3):285-9420880354
Cites: Nat Genet. 2000 Jul;25(3):324-810888883
Cites: Acta Neuropathol. 2001 Jan;101(1):17-2111194935
Cites: Nat Rev Genet. 2000 Dec;1(3):182-9011252747
Cites: Neurology. 2001 Jun 26;56(12):1690-611425935
Cites: Nat Genet. 2001 Aug;28(4):309-1011479587
Cites: Am J Med Genet. 2002 Apr 8;114(3):288-9111920850
Cites: Nature. 2002 Apr 4;416(6880):535-911932745
Cites: Science. 2002 Jun 21;296(5576):2225-912029063
Cites: Science. 2002 Jul 19;297(5580):353-612130773
Cites: Arch Neurol. 2002 Nov;59(11):1793-912433268
Cites: Ann N Y Acad Sci. 2002 Nov;977:37-4412480732
Cites: Ann N Y Acad Sci. 2002 Nov;977:162-812480747
Cites: Brain. 1969 Mar;92(1):147-564237656
Cites: N Engl J Med. 1989 Jun 1;320(22):1446-522566117
Cites: Acta Neuropathol. 1990;79(5):569-721691573
Cites: Science. 1990 Jun 1;248(4959):1124-62111584
Cites: Nature. 1991 Feb 21;349(6311):704-61671712
Cites: Neurology. 1991 Apr;41(4):479-862011243
Cites: Am J Med Genet. 1991 Sep 15;40(4):449-531684090
Cites: Acta Neuropathol. 1991;82(4):239-591759558
Cites: Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-818446617
Cites: Science. 2009 Mar 13;323(5920):1473-719286555
Cites: Acta Neuropathol. 2009 Jul;118(1):115-3019225789
Cites: Acta Neuropathol. 2009 Oct;118(4):475-8519513731
Cites: N Engl J Med. 1995 Nov 9;333(19):1242-77566000
Cites: Ann N Y Acad Sci. 1997 Sep 26;826:263-719329698
Cites: Ann Neurol. 1998 Mar;43(3):380-39506555
Cites: Neurosci Lett. 1999 Jul 9;269(2):67-7010430506
Cites: Ann Neurol. 1999 Sep;46(3):382-9010482269
Cites: Bioinformatics. 2005 Jan 15;21(2):263-515297300
Cites: Neurobiol Aging. 2005 Nov-Dec;26(10):1329-4116243604
Cites: Neuropathol Appl Neurobiol. 2005 Dec;31(6):589-9916281907
Cites: Nat Genet. 2006 Jan;38(1):24-616369530
Cites: BMC Neurol. 2006;6:216401346
Cites: Am J Hum Genet. 2006 Jun;78(6):936-4616685645
Cites: Brain. 2006 Nov;129(Pt 11):2977-8316921174
Cites: Brain. 2006 Nov;129(Pt 11):2984-9116931535
Cites: Neurology. 2007 Feb 27;68(9):684-717325276
Cites: Am J Med Genet B Neuropsychiatr Genet. 2007 Jun 5;144B(4):469-7417427190
Cites: Am J Hum Genet. 2007 Sep;81(3):559-7517701901
Cites: Neurobiol Aging. 2008 Feb;29(2):194-20217112637
Cites: Ann Neurol. 2008 Sep;64(3):348-5218661559
Cites: Nat Genet. 2009 Oct;41(10):1094-919734903
PubMed ID
21654062 View in PubMed
Less detail